Article

April 12, 2012

Felix Frueh, PhD, Speaks about the Health Economics of Personalized Medicine

In this video, Felix Frueh, PhD, President, Medco Research, discusses the advancements in personalized medicine over the past decade. Dr. Frueh also speaks about the clinical data that are being generated in order to prove to payers that this area of medicine is not only valuable but also affordable.

In this video, Felix Frueh, PhD, President, Medco Research, discusses the advancements in personalized medicine over the past decade. Dr. Frueh also speaks about the clinical data that are being generated in order to prove to payers that this area of medicine is not only valuable but also affordable.

This video was taken at CBI's 4th Annual Forum for Payers on Personalized Medicine conference in Washington, DC, on March 13, 2012.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Dr Sundar Jagannath

Andrew Kuykendall, MD, Moffitt Cancer Center

Dr Sundar Jagannath

Hadar Avihai Lev-Tov, MD

Ayodeji Adegunsoye, MD, PhD, MSc

David J. Maron, MD, FASPC, Stanford University School of Medicine

Hadar Avihai Lev-Tov, MD

Senator Vincent Polistina (R, New Jersey)

Related Content

Headshots of Robyn Guo Ku, BS, a medical student; Tarannum Jaleel, MD, MS; and Daniela Kroshinsky, MD, MPH | Background image credit: ipopba - stock.adobe.com

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com

July 22nd 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

Managed Care Cast

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

Mina Massaro-Giordano, MD

July 18th 2025

Patients With Dry Eye Have More Treatment Options Than Ever Before: A Q&A With Mina Massaro-Giordano, MD

Julia Bonavitacola Mina Massaro-Giordano, MD

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important for quality of life.

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com

July 15th 2025

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

Related Content

Headshots of Robyn Guo Ku, BS, a medical student; Tarannum Jaleel, MD, MS; and Daniela Kroshinsky, MD, MPH | Background image credit: ipopba - stock.adobe.com

July 25th 2025

Navigating Pediatric Hidradenitis Suppurativa: A Q&A on Early Diagnosis and Effective Treatment

Laura Joszt, MA Robyn Guo Ku Tarannum Jaleel, MD, MS Daniela Kroshinsky, MD, MPH

Pediatric hidradenitis suppurativa faces diagnostic delays and stigma, while adalimumab shows superior drug survival compared with infliximab in children.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com

July 22nd 2025

Making Reflexive Testing the Standard of Care in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or immunohistochemistry, Robert Kratzke, MD, says.

Managed Care Cast

July 1st 2025

Why Collaborative Care Is the Path Forward for Mental Health Care: Anna Bobb, MPH

Giuliana Grossi Anna Bobb, MPH

Explore how the Collaborative Care Model enhances mental health access in this episode featuring Anna Bobb, MPH, executive director of the Path Forward coalition.

Mina Massaro-Giordano, MD

July 18th 2025

Patients With Dry Eye Have More Treatment Options Than Ever Before: A Q&A With Mina Massaro-Giordano, MD

Julia Bonavitacola Mina Massaro-Giordano, MD

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important for quality of life.

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com

July 15th 2025

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

Hayden E. Klein Robert Kratzke, MD

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions